BioLineRx Ltd. Files 6-K, Announces Press Release
Ticker: BLRX · Form: 6-K · Filed: May 6, 2024 · CIK: 1498403
Sentiment: neutral
Topics: filing, press-release
Related Tickers: BLRX
TL;DR
BLRX filed a 6-K for a press release. Check the release for news.
AI Summary
On May 6, 2024, BioLineRx Ltd. (NASDAQ: BLRX) filed a Form 6-K to report the issuance of a press release. The press release, filed as Exhibit 1, details information relevant to the company's ongoing operations and disclosures for the month of May 2024. No specific financial figures or new material events were detailed in the 6-K filing itself, beyond the announcement of the press release.
Why It Matters
This filing indicates that BioLineRx Ltd. has made a new public announcement, which may contain important updates for investors regarding the company's business or financial status.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new material financial information or significant operational changes.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- NASDAQ: BLRX (company) — Stock Ticker
- May 6, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on May 6, 2024, which is included as Exhibit 1 to the report.
What information is contained in the press release mentioned in the filing?
The filing states that the press release was issued on May 6, 2024, but does not detail its specific contents, only that it is filed as Exhibit 1.
Does this filing contain new financial results for BioLineRx Ltd.?
No, this Form 6-K filing does not contain new financial results; it serves to report the issuance of a press release.
What is the principal executive office address for BioLineRx Ltd.?
The principal executive offices of BioLineRx Ltd. are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Is BioLineRx Ltd. required to file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-05-06 07:14:18
Filing Documents
- zk2431388.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 30KB
- image00001.jpg (GRAPHIC) — 402KB
- 0001178913-24-001582.txt ( ) — 593KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On May 6, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: May 6, 2024